Treatments for paroxysmal supraventricular tachycardia: A review of current practice
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Treatments for paroxysmal supraventricular tachycardia : A review of current practice. / Rajan, Deepthi; Schmitt, Nicole.
I: World Heart Journal, Bind 12, Nr. 3, 2020, s. 257-268.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Treatments for paroxysmal supraventricular tachycardia
T2 - A review of current practice
AU - Rajan, Deepthi
AU - Schmitt, Nicole
N1 - Publisher Copyright: © Nova Science Publishers, Inc.
PY - 2020
Y1 - 2020
N2 - Background: Paroxysmal supraventricular tachycardia (PSVT) is a mostly benign heart condition characterised by unpredictable episodes of rapid pulse. Despite this, PSVT attacks impart great concern in patients and often lead to hospital admissions. Etripamil (formerly MSP-2017) is a novel drug undergoing clinical trials as an intranasally administered treatment for PSVT. This narrative review compares etripamil to contemporary practices against PSVT, including employment of Valsalva manoeuvres (VM), ice water immersion, and anti-arrhythmic drugs with side-effects involving drug-induced QT prolongation. Objective: This review will aid in determining whether etripamil is a feasible alternative to such existing therapies for PSVT. Methods: The literature search was conducted in PubMed and Google Scholar with a time limit from 2013-2018. Results: Etripamil showed higher reversion to sinus rhythm than the VM-the currently most employed therapy for PSVT that patients can perform at home. Etripamil has not been shown to prolong QT intervals, as opposed to anti-arrhythmic drugs such as flecainide and amiodarone. Comparing etripamil to ice water immersion methods was uninformative, as the previous trials were inconclusive. Conclusion: Etripamil offers a relatively safe self-treatment for PSVT, which could replace anti-arrhythmic drugs presenting with acquired long QT and other side-effects. Hospital visits are avoided, since patients can easily administer the nasal spray at home. However, the safety and efficacy of usage is yet to be determined by the Phase III trial. The VM can be performed in patients experiencing PSVT as a preliminary therapy or employed in cases where etripamil fails to restore sinus rhythm.
AB - Background: Paroxysmal supraventricular tachycardia (PSVT) is a mostly benign heart condition characterised by unpredictable episodes of rapid pulse. Despite this, PSVT attacks impart great concern in patients and often lead to hospital admissions. Etripamil (formerly MSP-2017) is a novel drug undergoing clinical trials as an intranasally administered treatment for PSVT. This narrative review compares etripamil to contemporary practices against PSVT, including employment of Valsalva manoeuvres (VM), ice water immersion, and anti-arrhythmic drugs with side-effects involving drug-induced QT prolongation. Objective: This review will aid in determining whether etripamil is a feasible alternative to such existing therapies for PSVT. Methods: The literature search was conducted in PubMed and Google Scholar with a time limit from 2013-2018. Results: Etripamil showed higher reversion to sinus rhythm than the VM-the currently most employed therapy for PSVT that patients can perform at home. Etripamil has not been shown to prolong QT intervals, as opposed to anti-arrhythmic drugs such as flecainide and amiodarone. Comparing etripamil to ice water immersion methods was uninformative, as the previous trials were inconclusive. Conclusion: Etripamil offers a relatively safe self-treatment for PSVT, which could replace anti-arrhythmic drugs presenting with acquired long QT and other side-effects. Hospital visits are avoided, since patients can easily administer the nasal spray at home. However, the safety and efficacy of usage is yet to be determined by the Phase III trial. The VM can be performed in patients experiencing PSVT as a preliminary therapy or employed in cases where etripamil fails to restore sinus rhythm.
KW - Anti-arrhythmic
KW - Etripamil
KW - Ice water immersion
KW - Paroxysmal supraventricular tachycardia
KW - Valsalva manoeuvre
UR - http://www.scopus.com/inward/record.url?scp=85105760280&partnerID=8YFLogxK
M3 - Review
AN - SCOPUS:85105760280
VL - 12
SP - 257
EP - 268
JO - World Heart Journal
JF - World Heart Journal
SN - 1556-4002
IS - 3
ER -
ID: 290258891